vk2735
NASH
Viking Therapeutics, Inc.Phase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
130 Active assets in the NASH cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Resmetirom City University of New York | Phase 4 | BBB |
Pentoxifylline Al-Azhar University | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
Semaglutide Cascade Pharmaceuticals, Inc | Phase 4 | BBB |
Firsocostat Gilead Sciences | Phase 2 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →